pioglitazone has been researched along with Calcinosis in 11 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Calcinosis: Pathologic deposition of calcium salts in tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Atherosclerosis was induced via a high-cholesterol diet and endothelial denudation." | 5.48 | Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An ( Feng, T; Li, J; Nie, M; Xu, J; Xu, Z; Yan, Y; Zhang, M; Zhao, Q; Zhao, X, 2018) |
| "Valvular inflammation triggered by hyperlipidemia has been considered as an important initial process of aortic valve disease; however, cellular and molecular evidence remains unclear." | 1.72 | Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia. ( Ahn, HS; Ann, SJ; Choi, JH; Chung, J; Go, DM; Han, I; Jeong, SC; Kim, DY; Kim, K; Kim, KW; Kim, M; Kim, N; Kim, TK; Lee, HO; Lee, S; Lee, SH; Lee, SP; Oh, GT; Park, J; Park, JH; Park, KS; Park, SE; Park, WY; Shim, D; Woo, SH; Yoon, WK; Zhang, JY, 2022) |
| "Atherosclerosis was induced via a high-cholesterol diet and endothelial denudation." | 1.48 | Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An ( Feng, T; Li, J; Nie, M; Xu, J; Xu, Z; Yan, Y; Zhang, M; Zhao, Q; Zhao, X, 2018) |
| "Treatment with pioglitazone prevented abnormal valve calcification, but did not protect valve function." | 1.42 | Spontaneous Aortic Regurgitation and Valvular Cardiomyopathy in Mice. ( Baumbach, GL; Brooks, RM; Chen, B; Chu, Y; Davis, MK; Doshi, H; El Accaoui, RN; Funk, ND; Hajj, GP; Hameed, T; Heistad, DD; Leinwand, LA; Lund, DD; Magida, JA; Song, LS; Weiss, RM; Zimmerman, KA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Assmann, AK | 1 |
| Goschmer, D | 1 |
| Sugimura, Y | 2 |
| Chekhoeva, A | 1 |
| Barth, M | 2 |
| Assmann, A | 1 |
| Lichtenberg, A | 2 |
| Akhyari, P | 2 |
| Katahira, S | 1 |
| Grupp, S | 1 |
| Doepp, R | 1 |
| Selig, JI | 1 |
| Lee, SH | 3 |
| Kim, N | 1 |
| Kim, M | 1 |
| Woo, SH | 1 |
| Han, I | 1 |
| Park, J | 1 |
| Kim, K | 2 |
| Park, KS | 1 |
| Shim, D | 1 |
| Park, SE | 1 |
| Zhang, JY | 1 |
| Go, DM | 1 |
| Kim, DY | 1 |
| Yoon, WK | 1 |
| Lee, SP | 1 |
| Chung, J | 1 |
| Kim, KW | 1 |
| Park, JH | 1 |
| Lee, S | 1 |
| Ann, SJ | 1 |
| Ahn, HS | 1 |
| Jeong, SC | 1 |
| Kim, TK | 1 |
| Oh, GT | 1 |
| Park, WY | 1 |
| Lee, HO | 1 |
| Choi, JH | 1 |
| Xu, J | 1 |
| Nie, M | 1 |
| Li, J | 1 |
| Xu, Z | 1 |
| Zhang, M | 1 |
| Yan, Y | 1 |
| Feng, T | 1 |
| Zhao, X | 1 |
| Zhao, Q | 1 |
| Hajj, GP | 2 |
| Chu, Y | 2 |
| Lund, DD | 2 |
| Magida, JA | 1 |
| Funk, ND | 1 |
| Brooks, RM | 2 |
| Baumbach, GL | 1 |
| Zimmerman, KA | 1 |
| Davis, MK | 1 |
| El Accaoui, RN | 1 |
| Hameed, T | 1 |
| Doshi, H | 2 |
| Chen, B | 1 |
| Leinwand, LA | 1 |
| Song, LS | 1 |
| Heistad, DD | 2 |
| Weiss, RM | 2 |
| Clementi, F | 1 |
| Di Luozzo, M | 1 |
| Mango, R | 1 |
| Luciani, G | 1 |
| Trivisonno, A | 1 |
| Pizzuto, F | 1 |
| Martuscelli, E | 1 |
| Mehta, JL | 1 |
| Romeo, F | 1 |
| Davidson, MH | 1 |
| Beam, CA | 1 |
| Haffner, S | 1 |
| Perez, A | 1 |
| D'Agostino, R | 1 |
| Mazzone, T | 1 |
| Li, F | 1 |
| Cai, Z | 1 |
| Chen, F | 1 |
| Shi, X | 1 |
| Zhang, Q | 1 |
| Chen, S | 1 |
| Shi, J | 1 |
| Wang, DW | 1 |
| Dong, N | 1 |
| Sigmund, CD | 1 |
| Gaillard, V | 2 |
| Casellas, D | 1 |
| Seguin-Devaux, C | 1 |
| Schohn, H | 1 |
| Dauça, M | 2 |
| Atkinson, J | 2 |
| Lartaud, I | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Pioglitazone Treatment in Patient's Calcific Aortic Valve Disease With Mild Aortic Valve Stenosis[NCT05875675] | Phase 2 | 100 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent[NCT00376870] | Phase 3 | 160 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pioglitazone and Calcinosis
| Article | Year |
|---|---|
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study.
Topics: Aged; Calcinosis; Carotid Artery Diseases; Chi-Square Distribution; Coronary Artery Disease; Diabete | 2010 |
10 other studies available for pioglitazone and Calcinosis
| Article | Year |
|---|---|
A Role for Peroxisome Proliferator-Activated Receptor Gamma Agonists in Counteracting the Degeneration of Cardiovascular Grafts.
Topics: Animals; Aortic Valve; Aortic Valve Insufficiency; Bioprosthesis; Calcinosis; Chondrogenesis; Cryopr | 2021 |
PPAR-Gamma Activation May Inhibit the In Vivo Degeneration of Bioprosthetic Aortic and Aortic Valve Grafts under Diabetic Conditions.
Topics: Animals; Aorta; Aortic Valve; Aortic Valve Stenosis; Blood Glucose; Body Weight; Calcinosis; Diabete | 2021 |
Single-cell transcriptomics reveal cellular diversity of aortic valve and the immunomodulation by PPARγ during hyperlipidemia.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cells, Cultured; Endothelial Cells; Humans | 2022 |
Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An
Topics: Animals; Atherosclerosis; Calcinosis; Fluorodeoxyglucose F18; Hypoglycemic Agents; Inflammation; Mal | 2018 |
Spontaneous Aortic Regurgitation and Valvular Cardiomyopathy in Mice.
Topics: Actins; Animals; Aortic Valve; Aortic Valve Insufficiency; Calcinosis; Cell Death; Disease Progressi | 2015 |
Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combinatio | 2009 |
Pioglitazone attenuates progression of aortic valve calcification via down-regulating receptor for advanced glycation end products.
Topics: Animals; Aortic Valve; Aortic Valve Stenosis; Calcinosis; Cell Differentiation; Down-Regulation; Dru | 2012 |
Pioglitazone attenuates valvular calcification induced by hypercholesterolemia.
Topics: Adiponectin; Animals; Aorta; Aortic Valve; Aortic Valve Stenosis; Apolipoprotein B-100; Apoptosis; B | 2013 |
Pioglitazone improves aortic wall elasticity in a rat model of elastocalcinotic arteriosclerosis.
Topics: Animals; Aorta; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Blood Pressure; Calcinosis; Cyto | 2005 |
[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity].
Topics: Animals; Aorta; Arteries; Calcinosis; Elasticity; Hypertrophy, Left Ventricular; Hypoglycemic Agents | 2007 |